Innovations such as biologics and personalized medicine promise new levels of clinical effectiveness. However, willingness to pay is not limitless, especially in the context of soaring drug prices and an increasing focus among payers, providers, and policymakers on lowering healthcare costs.

Total product value, both economic and clinical, has become the essential basis for differentiation and maintaining premium pricing – and that’s why it must be the foundation for all portfolio management decisions. We’ve explained the key requirements for shifting your organization toward this way of thinking in our recently published article, Managing Portfolios to Deliver Economic and Clinical Value.